Clinical profile and outcome of children with Neuroblastoma: A single center retrospective study from North India

Pediatric Hematology Oncology Journal Pub Date : 2025-06-11 DOI:10.1016/j.phoj.2025.100466

Zaibaish Khan, Nishant Verma

{"title":"Clinical profile and outcome of children with Neuroblastoma: A single center retrospective study from North India","authors":"Zaibaish Khan, Nishant Verma","doi":"10.1016/j.phoj.2025.100466","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>With advances in pediatric oncology care, the outcome of children with neuroblastoma has improved. However, in low and middle-income countries (LMICs), the survival rate remains low. This study was conducted because of the paucity of data regarding the clinico-epidemiological profile and outcome of children with neuroblastoma in India.</div></div><div><h3>Methods</h3><div>Children (<13 y) with neuroblastoma treated at our centre between 2016 and 2022 were retrospectively analyzed.</div></div><div><h3>Results</h3><div>Over the 7-year study period, 53 children with neuroblastoma were treated at our centre. The age ranged from 1 month to 13 years (male: female ratio: 2.3:1). Adrenal was the most common primary site (58%). The majority of children had stage 4 disease (58.5%). The projected 2-year overall survival is 30%, whereas the event-free survival is 24.5%.</div></div><div><h3>Conclusions</h3><div>Children with neuroblastoma in our setting presented late with advanced disease. Even with a multidisciplinary approach, the survival rate for patients with advanced disease were still poor.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"10 3","pages":"Article 100466"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124525000348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

With advances in pediatric oncology care, the outcome of children with neuroblastoma has improved. However, in low and middle-income countries (LMICs), the survival rate remains low. This study was conducted because of the paucity of data regarding the clinico-epidemiological profile and outcome of children with neuroblastoma in India.

Methods

Children (<13 y) with neuroblastoma treated at our centre between 2016 and 2022 were retrospectively analyzed.

Results

Over the 7-year study period, 53 children with neuroblastoma were treated at our centre. The age ranged from 1 month to 13 years (male: female ratio: 2.3:1). Adrenal was the most common primary site (58%). The majority of children had stage 4 disease (58.5%). The projected 2-year overall survival is 30%, whereas the event-free survival is 24.5%.

Conclusions

Children with neuroblastoma in our setting presented late with advanced disease. Even with a multidisciplinary approach, the survival rate for patients with advanced disease were still poor.

查看原文本刊更多论文

北印度儿童神经母细胞瘤的临床特征和预后：一项单中心回顾性研究

背景：随着小儿肿瘤治疗的进步，神经母细胞瘤患儿的预后得到了改善。然而，在低收入和中等收入国家（LMICs），存活率仍然很低。由于缺乏有关印度神经母细胞瘤儿童的临床流行病学概况和预后的数据，因此进行了本研究。方法回顾性分析2016年至2022年在我中心治疗的神经母细胞瘤患儿（<；13岁）。结果在7年的研究期间，53例神经母细胞瘤患儿在本中心接受了治疗。年龄1个月~ 13岁，男女比例为2.3:1。肾上腺是最常见的原发部位（58%）。大多数儿童为4期疾病（58.5%）。预计2年总生存率为30%，而无事件生存率为24.5%。结论本院儿童神经母细胞瘤发病较晚，病程较晚。即使采用多学科方法，晚期患者的生存率仍然很低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Hematology Oncology Journal

CiteScore

1.00

自引率

0.00%

发文量